Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExIST baricitinib prevention study in individuals at risk of inflammatory arthritis
ISRCTN53678960Phase 2Active, not recruiting
- Sponsor
- University of Leeds
- Start
- Dec 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib in autoimmune arthritis (2 arms), sponsored by University of Leeds. Primary endpoint: Proportion developing inflammatory arthritis by 48 weeks. Started Dec 2022; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
autoimmune arthritis
Beyond the preview
Go deeper on ISRCTN53678960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53678960.